Tracking Prostate Cancer Response Using PSMA Imaging Scans
Part of Cancer, Kidney & urinary clinical trials.
This study uses a special type of imaging scan (PSMA PET) to track how well prostate cancer treatment is working by comparing scans before and after your planned therapy. The goal is to help doctors better understand which treatments work best for your type of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Recently diagnosed with prostate cancer confirmed by biopsy, with a Gleason score of 7 or higher (indicating more aggressive cancer)
- Planning to start cancer treatment soon—either surgery, radiation, hormone therapy, chemotherapy, or a combination
- Able to undergo two imaging scans (PSMA PET/CT): one before treatment starts and one after
- 18 years old or older
- Willing and able to attend follow-up appointments as scheduled
- No prior prostate cancer treatments (surgery, radiation, chemotherapy, or hormone therapy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET/CT scan with a radioactive tracer (PSMA) to get detailed images of the pelvis in men with high-risk prostate cancer. The goal is to improve cancer staging and detect recurrence more accurately.
This study looks at whether a special scan called PSMA PET can help predict how prostate cancer will progress. It is for people who have just been diagnosed and have not started treatment yet.
This study uses a special type of scan called a PSMA PET to see how well different prostate cancer treatments are working. It is for people with advanced prostate cancer who are about to start or change systemic therapy.
This study is testing whether a special scan (dosimetry) can help predict how well PSMA radioligand therapy works for men with advanced prostate cancer that has spread. The therapy uses a radioactive drug to target and kill cancer cells that have a protein called PSMA.
This Phase 3 study checks whether a PSMA PET/CT scan (using a special tracer) can help doctors make better decisions for people with prostate cancer after treatment, based on PSA blood test changes. It may help identify whether cancer has spread or how to plan next steps.
This study uses a special scan (PSMA PET/CT) to see how well a new type of hormone therapy is working in men whose prostate cancer has spread to other parts of the body. The goal is to find out if the scan can help doctors track the cancer's response to treatment over time.
Hear when a new High Risk Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.